Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
Nael Aldweib, Nathan J. Verlinden, Hayah Kassis‐George, Amresh Raina
Abstract
There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable pulmonary arterial hypertension patients using a standardized protocol in the outpatient setting.
Topics & Concepts
MedicinePulmonary Hypertension Research and TreatmentsHeart Failure Treatment and ManagementAtrial Fibrillation Management and Outcomes